04Dic 2013
wiley-logo

In conclusion, our data highlight the potential for novel drug targeting approaches in rare skeletal disorders ranging from severe skeletal fragility to sclerosing bone overgrowth through selective modulation of canonical WNT signaling.

These approaches should also be beneficial in the context of other medical conditions with much less severe phenotypes, such as postmenopausal osteoporosis, given the crucial role of this potent bone anabolic pathway for skeletal homeostasis

Autor: Ming‐Kang Chang, Ina Kramer, Hansjoerg Keller,…
04Nov 2013
Springer

Osteoporos Int (2014) 25:1225–1235

This is the first network meta-analysis to assess the comparative GI safety of bisphosphonates for primary osteoporosis. Our results identify zoledronic acid as having the highest probability of having the greatest number of GI adverse events and nausea. Discontinuation due to adverse events may be a more clinically relevant outcome, with the highest probability of greatest occurrence found with etidronate and zoledronic acid. These results question the assumption that annual zoledronic acid will translate into better adherence. Little difference was found between alendronate and risedronate for serious AE. More research into real-world implications of the comparative safety of bisphosphonates is needed.

Autor: M. Tadrous, L. Wong,M. M. Mamdani,D. N. Juurlink ,M. D. Krahn,L. E. Lévesque ,S. M. Cadarette
04Sep 2013
wiley-logo

J Bone Miner Res, (2014) 29; 787–795

The findings represent the first demonstration, using a direct in vivo measure of BMS, of compromised bone material properties in patients with T2D. Further, our results confirm previous studies demonstrating low bone turnover in patients with T2D and highlight the potential detrimental effects of prolonged hyperglycemia on bone quality. Thus, the skeleton needs to be recognized as another important target tissue subject to diabetic complications.

Autor: J N Farr,1 M T Drake,1 S Amin,2 L J Melton III,3 L K McCready,1 Sundeep Khosla1
04Ago 2013
Springer

In conclusion, baseline cardiovascular diseases are common in patients treated with strontium ranelate, with more than half of strontium ranelate users being current

users of antiplatelet drugs or having a history of cerebrovascular disease, peripheral vascular disease or myocardial infarction. Moreover, this observational study shows an increased confounder-adjusted mortality risk in patients treated with strontium ranelate compared with other osteoporosis drugs.

Autor: B. Abrahamsen, E. L. Grove, P. Vestergaard
04Jun 2013
europepmc_logo

Froedtert Healthcare, Patient Care Services, Milwaukee, WI, USA, ryanpa@uwm.edu.

Ryan P, Schlidt A, Ryan C
Froedtert Healthcare, Patient Care Services, Milwaukee, WI, USA, ryanpa@uwm.edu.
Osteoporosis International : a Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA [2013]

Autor: Journal Established as Result of Cooperation Between…
04Feb 2013
american-journal-of-medicine-logo

Vertebral fractures detected “incidentally” by chest radiograph usually do not trigger osteoporosis treatment in older patients.

Background

Vertebral fractures detected “incidentally” by chest radiograph usually do not trigger osteoporosis treatment in older patients. In a 3-arm controlled trial we reported that both physician-directed and enhanced (physician plus patient activation) interventions increased treatment rates more than 10-fold (15%-20% absolute increases) compared with usual care; the cost-effectiveness of these interventions is unknown.

Sumit R. Majumdar, MD, MPHcorrespondencePress enter key for correspondence informationemailPress enter key to Email the author, Douglas A. Lier, MA, Finlay A. McAlister, MD, MSc, Brian H. Rowe, MD, MSc, Kerry Siminoski, MD, David A. Hanley, MD, Anthony S. Russell, MD, Jeffrey A. Johnson, PhD

04Oct 2012
Springer

In paired biopsies of osteoporotic women treated with either strontium ranelate or a placebo for 36 months, characteristics of bone apatite crystals were not influenced by the presence of strontium.

Summary

In paired biopsies of osteoporotic women treated with either strontium ranelate or a placebo for 36 months, characteristics of bone apatite crystals were not influenced by the presence of strontium. The mean rate of substitutions of calcium by strontium ions was 4.5 %.

Autor: A. Doublier, D. Farlay, X. Jaurand, R. Vera, G. Boivin
05Ago 2012
oxford_logo

Frederiek van den Bos1,2, Arlene D. Speelman3, Monique Samson1, Marten Munneke4,5, Bastiaan R. Bloem6 and, Harald J. J. Verhaar1

 Conclusion: bone loss in PD is multifactorial. It is clinically important because of the concomitant risk of fractures. Screening for osteoporosis should be considered more often, and therapeutic interventions should be initiated.
Autor: F. van den Bos. Email: f.vandenbos@hagaziekenhuis.nl
04May 2012
Springer

To reveal the mechanism of inflammation-accompanied osteoporosis, mouse CD11b cells and CD4+CD25+ T cells were cocultured. Our results showed that CD11b+ monocytes cocultured with CD4+CD25+ T cells generated significantly less osteoclasts than those cocultured with CD4+CD25− T cells. The levels of MMP-7 and 9 in coculture supernatant were decreased significantly when CD11b+ monocytes and CD4+CD25+ T cells were cocultured comparing to the CD4+CD25− T cell group. These results highlight the role of CD4+CD25+ T cells on rheumatic osteoporosis.

Autor: P. T. Yang, X. H. Meng, Y. Yang, W. G. Xiao
04Mar 2012
Springer

The secreted protein acidic and rich in cysteine (SPARC), also known as osteonectin, plays an important role in osteoblast formation, maturation, and survival.

Summary

The secreted protein acidic and rich in cysteine (SPARC), also known as osteonectin, plays an important role in osteoblast formation, maturation, and survival. Here, we report the effects of recombinant human parathyroid hormone (1-34) [rhPTH (1-34)], a bone formation-stimulating agent, and elcatonin on plasma SPARC levels in patients with osteoporosis. The rhPTH (1-34) treatment significantly increased plasma SPARC levels, and the change of plasma SPARC correlated positively with changes of lumbar bone mineral density (BMD) at L2–L4. These results unveil that SPARC may be a novel marker related to the regulation of bone formation.

Autor: L. Zhang, L. Li, M. Yang, K. Xu, G. Boden, G. Yang